Company intelligence / Profile preview

Kinaset Therapeutics

Medfield, Massachusetts, United Stateskinasettherapeutics.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

Kinaset's lead candidate frevecitinib (KN-002), a novel inhaled pan-JAK inhibitor, has completed Phase 1 clinical trials showing clinically relevant reductions in fractional exhaled nitric oxide (FeNO) in patients with mild and moderate-to-severe asthma. The FDA has cleared its IND application, and the company plans to begin a Phase 2b dose ranging trial in mid-2025[8].

Therapeutic areas: Pulmonology
Modalities: Small molecule drugsinhaled therapeutics
Industry: Biotech

Drug pipeline

1 asset

frevecitinib

Beyond the preview

Go deeper on Kinaset Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinaset Therapeutics.

Explore the full profile